Arachidonate 5-lipoxygenase (5-lipoxygenase, 5-LO, 5-LOX or Alox5), which transforms EFAs into leukotrienes, is a current target for pharmaceutical intervention in a number of diseases. 5-LO is a target for pharmaceutical intervention in CAD.
Li N, Sood S, Wang S, Fang M, Wang P, Sun Z, Yang CS, Chen X.
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Clin Cancer Res. 2005 Mar 1;11(5):2089-96.
PMID
Sun Z, Sood S, Li N, Ramji D, Yang P, Newman RA, Yang CS, Chen X.
Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinoge
Resolvin E2: identification and anti-inflammatory actions: pivotal role
of human 5-lipoxygenase in resolvin E series biosynthesis.
Tjonahen E, Oh SF, Siegelman J, Elangovan S, Percarpio KB, Hong S,
Arita M, Serhan CN.
Chem Biol. 2006 Nov;13(11):1193-202.
PMID: 17114001
doi:10.1016/j.chembiol.2006.09.011
Lipoxins are a series of anti-inflammatory mediators. Lipoxins are short lived endogenously produced nonclassic eicosanoids whose appearance in inflammation signals the resolution of inflammation. They are abbreviated as LX, an acronym for lipoxygenase (LO) interaction products. At present two lipoxins have been identified; lipoxin A4 (LXA4) and lipoxin B4 (LXB4)